Objective: The biology of high grade serous ovarian carcinoma (HGSOC) is poorly understood. Little has been reported on intratumoral homogeneity or heterogeneity of primary HGSOC tumors and their metastases. We evaluated the global protein expression profiles of paired primary and metastatic HGSOC from formalin-fixed, paraffin-embedded (FFPE) tissue samples. Methods: After IRB approval, six patients with advanced HGSOC were identified with tumor in both ovaries at initial surgery. Laser capture microdissection (LCM) was used to extract tumor for protein digestion. Peptides were extracted and analyzed by reversed-phase liquid chromatography coupled to a linear ion trap mass spectrometer. Tandem mass spectra were searched against the UniProt human protein database. Differences in protein abundance between samples were assessed and analyzed by Ingenuity Pathway Analysis software. Immunohistochemistry (IHC) for select proteins from the original and an additional validation set of five patients was performed. Results: Unsupervised clustering of the abundance profiles placed the paired specimens adjacent to each other. IHC H-score analysis of the validation set revealed a strong correlation between paired samples for all proteins. For the similarly expressed proteins, the estimated correlation coefficients in two of three experimental samples and all validation samples were statistically significant ( p < 0.05). The estimated correlation coefficients in the experimental sample proteins classified as differentially expressed were not statistically significant. Conclusion: A global proteomic screen of primary HGSOC tumors and their metastatic lesions identifies tumoral homogeneity and heterogeneity and provides preliminary insight into these protein profiles and the cellular pathways they constitute.
References
[1]
Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62, 10–29, doi:10.3322/caac.20138.
Gerlinger, M.; Rowan, A.J.; Horswell, S.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.; Tarpey, P.; et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366, 883–892, doi:10.1056/NEJMoa1113205.
[5]
Cadron, I.; van Gorp, T.; Moerman, P.; Waelkens, E.; Vergote, I. Proteomic analysis of laser microdissected ovarian cancer tissue with SELDI-TOF MS. Methods Mol. Biol. 2011, 755, 155–163, doi:10.1007/978-1-61779-163-5_12.
[6]
Tian, Y.; Yao, Z.; Roden, R.B.; Zhang, H. Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics. Proteomics 2011, 11, 4677–4687, doi:10.1002/pmic.201000811.
[7]
Davidson, B. Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma. Curr. Cancer Drug Targets 2007, 7, 109–120, doi:10.2174/156800907780006904.
[8]
Espina, V.; Dettloff, K.A.; Cowherd, S.; Petricoin, E.F., 3rd.; Liotta, L.A. Use of proteomic analysis to monitor responses to biological therapies. Expert Opin. Biol. Ther. 2004, 4, 83–93, doi:10.1517/14712598.4.1.83.
[9]
Zorn, K.K.; Bonome, T.; Gangi, L.; Chandramouli, G.V.; Awtrey, C.S.; Gardner, G.J.; Barrett, J.C.; Boyd, J.; Birrer, M.J. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer Res. 2005, 11, 6422–6430, doi:10.1158/1078-0432.CCR-05-0508.
[10]
Klopfleisch, R.; Weiss, A.T.; Gruber, A.D. Excavation of a buried treasure—DNA, mRNA, miRNA and protein analysis in formalin fixed, paraffin embedded tissues. Histol. Histopathol. 2011, 26, 797–810.
[11]
Magdeldin, S.; Yamamoto, T. Toward deciphering proteomes of formalin-fixed paraffin-embedded (FFPE) tissues. Proteomics 2012, 12, 1045–1058, doi:10.1002/pmic.201100550.
[12]
Tanca, A.; Pagnozzi, D.; Addis, M.F. Setting proteins free: Progresses and achievements in proteomics of formalin-fixed, paraffin-embedded tissues. Proteomics Clin. Appl. 2012, 6, 7–21, doi:10.1002/prca.201100044.
[13]
Li, X.Q.; Zhang, S.L.; Cai, Z.; Zhou, Y.; Ye, T.M.; Chiu, J.F. Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma. Cancer Lett. 2009, 275, 109–116, doi:10.1016/j.canlet.2008.10.019.
[14]
Sethi, N.; Kang, Y. Unravelling the complexity of metastasis—Molecular understanding and targeted therapies. Nat. Rev. Cancer 2011, 11, 735–748, doi:10.1038/nrc3125.
[15]
Amon, L.M.; Law, W.; Fitzgibbon, M.P.; Gross, J.A.; O’Briant, K.; Peterson, A.; Drescher, C.; Martin, D.B.; McIntosh, M. Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer. PLoS One 2010, 5, e11137, doi:10.1371/journal.pone.0011137.
[16]
Elschenbroich, S.; Ignatchenko, V.; Clarke, B.; Kalloger, S.E.; Boutros, P.C.; Gramolini, A.O.; Shaw, P.; Jurisica, I.; Kislinger, T. In-depth proteomics of ovarian cancer ascites: Combining shotgun proteomics and selected reaction monitoring mass spectrometry. J. Proteome Res. 2011, 10, 2286–2299.
[17]
Hoskins, E.R.; Hood, B.L.; Sun, M.; Krivak, T.C.; Edwards, R.P.; Conrads, T.P. Proteomic analysis of ovarian cancer proximal fluids: Validation of elevated peroxiredoxin 1 in patient peripheral circulation. PLoS One 2011, 6, e25056.
[18]
Kim, S.W.; Kim, S.; Nam, E.J.; Jeong, Y.W.; Lee, S.H.; Paek, J.H.; Kim, J.H.; Kim, J.W.; Kim, Y.T. Comparative proteomic analysis of advanced serous epithelial ovarian carcinoma: Possible predictors of chemoresistant disease. OMICS 2011, 15, 281–292, doi:10.1089/omi.2010.0012.
[19]
An, H.J.; Kim, D.S.; Park, Y.K.; Kim, S.K.; Choi, Y.P.; Kang, S.; Ding, B.; Cho, N.H. Comparative proteomics of ovarian epithelial tumors. J. Proteome Res. 2006, 5, 1082–1090, doi:10.1021/pr050461p.
[20]
Bloom, G.C.; Eschrich, S.; Zhou, J.X.; Coppola, D.; Yeatman, T.J. Elucidation of a protein signature discriminating six common types of adenocarcinoma. Int. J. Cancer 2007, 120, 769–775, doi:10.1002/ijc.22041.
[21]
Cadron, I.; van Gorp, T.; Amant, F.; Vergote, I.; Moerman, P.; Waelkens, E.; Daemen, A.; van de Plas, R.; de Moor, B.; Zeillinger, R. The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles. Anticancer Res. 2009, 29, 1039–1045.
Ikeda, K.; Monden, T.; Kanoh, T.; Tsujie, M.; Izawa, H.; Haba, A.; Ohnishi, T.; Sekimoto, M.; Tomita, N.; Shiozaki, H.; et al. Extraction and analysis of diagnostically useful proteins from formalin-fixed, paraffin-embedded tissue sections. J. Histochem. Cytochem. 1998, 46, 397–403, doi:10.1177/002215549804600314.
[24]
Rodriguez-Rigueiro, T.; Valladares-Ayerbes, M.; Haz-Conde, M.; Blanco, M.; Aparicio, G.; Fernandez-Puente, P.; Blanco, F.J.; Lorenzo, M.J.; Aparicio, L.A.; Figueroa, A. A novel procedure for protein extraction from formalin-fixed paraffin-embedded tissues. Proteomics 2011, 11, 2555–2559, doi:10.1002/pmic.201000809.
[25]
Gustafsson, J.O.; Oehler, M.K.; McColl, S.R.; Hoffmann, P. Citric acid antigen retrieval (CAAR) for tryptic peptide imaging directly on archived formalin-fixed paraffin-embedded tissue. J. Proteome Res. 2010, 9, 4315–4328, doi:10.1021/pr9011766.
[26]
Ostasiewicz, P.; Zielinska, D.F.; Mann, M.; Wisniewski, J.R. Proteome, phosphoproteome, and N-glycoproteome are quantitatively preserved in formalin-fixed paraffin-embedded tissue and analyzable by high-resolution mass spectrometry. J. Proteome Res. 2010, 9, 3688–3700, doi:10.1021/pr100234w.
[27]
Magrane, M. UniProt Knowledgebase: A Hub of Integrated Protein Data. Available online: http://www.ebi.ac.uk/integr8 (accessed on 21 March 2013).
[28]
Keller, A.; Nesvizhskii, A.I.; Kolker, E.; Aebersold, R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 2002, 74, 5383–5392, doi:10.1021/ac025747h.
[29]
Keller, A.; Eng, J.; Zhang, N.; Li, X.J.; Aebersold, R. A uniform proteomics MS/MS analysis platform utilizing open XML file formats. Mol. Syst. Biol. 2005, 1, e2005.0017.
[30]
Liu, H.; Sadygov, R.G.; Yates, J.R., 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 2004, 76, 4193–4201, doi:10.1021/ac0498563.
[31]
Hood, B.L.; Conrads, T.P.; Veenstra, T.D. Mass spectrometric analysis of formalin-fixed paraffin-embedded tissue: Unlocking the proteome within. Proteomics 2006, 6, 4106–4114, doi:10.1002/pmic.200600016.
[32]
Hood, B.L.; Conrads, T.P.; Veenstra, T.D. Unravelling the proteome of formalin-fixed paraffin-embedded tissue. Brief. Funct. Genomic. Proteomic. 2006, 5, 169–175, doi:10.1093/bfgp/ell017.
[33]
Hood, B.L.; Grahovac, J.; Flint, M.S.; Sun, M.; Charro, N.; Becker, D.; Wells, A.; Conrads, T.P. Proteomic analysis of laser microdissected melanoma cells from skin organ cultures. J. Proteome Res. 2010, 9, 3656–3663, doi:10.1021/pr100164x.
Ding, L.; Ellis, M.J.; Li, S.; Larson, D.E.; Chen, K.; Wallis, J.W.; Harris, C.C.; McLellan, M.D.; Fulton, R.S.; Fulton, L.L.; et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464, 999–1005, doi:10.1038/nature08989.
[37]
Campbell, P.J.; Yachida, S.; Mudie, L.J.; Stephens, P.J.; Pleasance, E.D.; Stebbings, L.A.; Morsberger, L.A.; Latimer, C.; McLaren, S.; Lin, M.L.; et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467, 1109–1113, doi:10.1038/nature09460.
[38]
Chung, K.H.; Lee, D.H.; Kim, Y.; Kim, T.H.; Huh, J.H.; Chung, S.G.; Lee, S.; Lee, C.; Ko, J.J.; An, H.J. Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma. J. Proteome Res. 2010, 9, 451–457, doi:10.1021/pr900811x.
[39]
Basu, A.; Banerjee, H.; Rojas, H.; Martinez, S.R.; Roy, S.; Jia, Z.; Lilly, M.B.; de Leon, M.; Casiano, C.A. Differential expression of peroxiredoxins in prostate cancer: Consistent upregulation of PRDX3 and PRDX4. Prostate 2011, 71, 755–765, doi:10.1002/pros.21292.
[40]
Canet, B.; Pons, C.; Espinosa, I.; Prat, J. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior. Hum. Pathol. 2011, 42, 833–839, doi:10.1016/j.humpath.2010.08.022.
[41]
Gadducci, A.; Guerrieri, M.E.; Riccardo, G.A. New insights on the pathogenesis of ovarian carcinoma: Molecular basis and clinical implications. Gynecol. Endocrinol. 2012, 28, 582–586, doi:10.3109/09513590.2011.649595.
[42]
Lalwani, N.; Prasad, S.R.; Vikram, R.; Shanbhogue, A.K.; Huettner, P.C.; Fasih, N. Histologic, molecular, and cytogenetic features of ovarian cancers: Implications for diagnosis and treatment. Radiographics 2011, 31, 625–646, doi:10.1148/rg.313105066.
[43]
Shih, I.; Panuganti, P.K.; Kuo, K.T.; Mao, T.L.; Kuhn, E.; Jones, S.; Velculescu, V.E.; Kurman, R.J.; Wang, T.L. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am. J. Pathol. 2011, 178, 1442–1447, doi:10.1016/j.ajpath.2011.01.009.
[44]
McConechy, M.K.; Anglesio, M.S.; Kalloger, S.E.; Yang, W.; Senz, J.; Chow, C.; Heravi-Moussavi, A.; Morin, G.B.; Mes-Masson, A.M.; Australian Ovarian Cancer Study Group; et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J. Pathol. 2011, 223, 567–573, doi:10.1002/path.2848.
